Objective: To describe SCORE-VN cardiovascular risk stratification and explore associations between selected characteristics not directly included in the SCORE-VN inputs and high–very high risk among male inpatients with primary gout. Methods: This cross-sectional study included 135 men aged 40–69 years with primary gout diagnosed according to the 2015 ACR/EULAR criteria and admitted to Nam Dinh General Hospital from August 2025 to August 2026. SCORE-VN was calculated using age, sex, smoking, systolic blood pressure, total cholesterol and HDL-C. Logistic regression estimates are reported as odds ratios (ORs) and 95% confidence intervals (CIs), not as risk ratios. Results: The mean SCORE-VN was 11.01 ± 7.67%; 77.04% were classified as high–very high risk and 53.33% as very high risk. In a six-variable model, gout duration ≥5 years (aOR 9.66; 95% CI 2.91–32.10; p<0.001), tophi (aOR 3.92; 95% CI 1.09–14.09; p=0.036), and ≥2 gout flares/year (aOR 13.46; 95% CI 3.33–54.41; p<0.001) were associated with high–very high SCORE-VN classification. Conclusion: High–very high SCORE-VN classification was common in this selected sample of male inpatients with primary gout. The observed associations are cross-sectional and do not establish causality or predict observed cardiovascular events.
SCORE-VN CARDIOVASCULAR RISK STRATIFICATION AND ASSOCIATED FACTORS AMONG MALE INPATIENTS WITH PRIMARY GOUT AT NAM DINH GENERAL HOSPITAL, 2025–2026
2
Views
0
Downloads
Abstract
Keywords
primary gout; SCORE-VN; cardiovascular risk stratification; tophi; gout flares.
References
[1]
1. Ferguson LD, Molenberghs G, Verbeke G, et al. Gout and incidence of 12 cardiovascular diseases: a case-control study. Lancet Rheumatol. 2024;6(3):e156–e167.
Google Scholar
[2]
2. Pei H, He L, Wang S, et al. Association between gout and cardiovascular disease: a register-based cohort study. Prog Cardiovasc Dis. 2026. doi:10.1016/j.pcad.2026.02.003.
Google Scholar
[3]
3. Cox P, Gupta S, Zhao S, Hughes D. The incidence and prevalence of cardiovascular diseases in gout: a systematic review and meta-analysis. Rheumatol Int. 2021;41:1209–1219.
Google Scholar
[4]
4. Cipolletta E, Tata LJ, Nakafero G, et al. Association between gout flares and subsequent cardiovascular events. JAMA. 2022;328(5):440–450.
Google Scholar
[5]
5. Ghang B, Kim J, Kang T, Kim HJ. Ten-year cardiovascular risk changes and major adverse events in gout patients. Rheumatology. 2025. doi:10.1093/rheumatology/keaf322.
Google Scholar
[6]
6. López-González R, et al. Cardiovascular risk assessment in patients with gout using SCORE2. Reumatol Clin. 2022;18(8):450–456.
Google Scholar
[7]
7. Neogi T, Jansen TL, Dalbeth N, et al. 2015 gout classification criteria: an ACR/EULAR collaborative initiative. Ann Rheum Dis. 2015;74(10):1789–1798.
Google Scholar
[8]
8. Bộ Y tế. Quyết định số 5333/QĐ-BYT ngày 25/11/2021 ban hành Hướng dẫn chẩn đoán và điều trị bệnh tim mạch. Hà Nội; 2021.
Google Scholar
[9]
9. Hội Tim mạch học Việt Nam. Khuyến cáo về chẩn đoán và điều trị tăng huyết áp. Nhà xuất bản Y học; 2022.
Google Scholar
[10]
10. National Cholesterol Education Program Expert Panel. Third Report (NCEP-ATP III) Final Report. Circulation. 2002;106(25):3143–3421.
Google Scholar
[11]
11. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–163.
Google Scholar
[12]
12. Hội Tim mạch học Việt Nam và Hội Tim mạch Can thiệp Việt Nam. Công cụ đánh giá nguy cơ tim mạch SCORE-VN. Hà Nội; 2021.
Google Scholar
[13]
13. Nguyễn Lê Phương Thảo, Nguyễn Vĩnh Ngọc, Lê Thị Liễu, và cs. Khảo sát nguy cơ tim mạch trong 10 năm theo thang điểm ASCVD ở bệnh nhân gút. Tạp chí Y học Việt Nam. 2025;557(2). doi:10.51298/vmj.v557i2.16684.
Google Scholar
[14]
14. Andrés M, Quintanilla MA, Sivera F, et al. Silent monosodium urate crystal deposits are associated with severe coronary calcification. Arthritis Rheumatol. 2016;68(6):1531–1539.
Google Scholar